Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab as adjunct treatment to prevent vaso-occlusive episodes in sickle cell disease
2020-004839-25Phase 2Active
- Sponsor
- Roche
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sickle cell disease (SCD) and vaso-occlusive crisis (VOC) comparing Crovalimab with Placebo (2 arms). Primary endpoint: Annualized rate of medical facility vaso-occlusive episodes (AVR). Started Jul 2021; status: active.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on 2020-004839-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004839-25.